Based on the Terns Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Terns Pharmaceuticals Inc is USD 14.83 over the next 12 months. Terns Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Terns Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Terns Pharmaceuticals Inc’s stock price was USD 2.40. Terns Pharmaceuticals Inc’s stock price has changed by +17.07% over the past week, -24.53% over the past month and -52.57% over the last year.
No recent analyst target price found for Terns Pharmaceuticals Inc
No recent average analyst rating found for Terns Pharmaceuticals Inc
Company Overview Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Read Less
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial fo...Read More
Frequently Asked Questions About Terns Pharmaceuticals Inc (TERN) Stock
Based on ratings from 4 analysts Terns Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on TERN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TERN is USD 14.83 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TERN's stock to indicate if its overvalued.
The last closing price of TERN's stock was USD 2.40.
The most recent market capitalization for TERN is USD 0.19B.
Based on targets from 4 analysts, the average taret price for TERN is projected at USD 14.83 over the next 12 months.
This means that TERN's stock price may go up by +518.06% over the next 12 months.
We can't find any ETFs which contains Terns Pharmaceuticals Inc's stock.
As per our most recent records Terns Pharmaceuticals Inc has 59 Employees.
Terns Pharmaceuticals Inc's registered address is 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404.
You can get more information about it from Terns Pharmaceuticals Inc's website at https://www.ternspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Terns Pharmaceuticals Inc (TERN) Stock
Based on ratings from 4 analysts Terns Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on TERN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TERN is USD 14.83 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on TERN's stock to indicate if its overvalued.
The last closing price of TERN's stock was USD 2.40.
The most recent market capitalization for TERN is USD 0.19B.
Based on targets from 4 analysts, the average taret price for TERN is projected at USD 14.83 over the next 12 months.
This means that TERN's stock price may go up by +518.06% over the next 12 months.
We can't find any ETFs which contains Terns Pharmaceuticals Inc's stock.
As per our most recent records Terns Pharmaceuticals Inc has 59 Employees.
Terns Pharmaceuticals Inc's registered address is 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404.
You can get more information about it from Terns Pharmaceuticals Inc's website at https://www.ternspharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TERN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
